Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

Diabetes Research and Clinical Practice

Volumn 71, Issue 2, 2006, Pages 210-219

  Sengul, Ahmet M ^a   Altuntas, Yüksel ^a   Kürklü, Akin ^a   Aydin, Levent ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Combination therapy; Diabetes mellitus; Hypertension; Lisinopril; Microalbuminuria; Telmisartan

Indexed keywords

ALBUMIN; LISINOPRIL; TELMISARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RETINOPATHY; STOMACH DISEASE; SYSTOLIC BLOOD PRESSURE; WEAKNESS;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CREATININE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 30944451141     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.06.010     Document Type: Article

References (43)

1. H.H. Parving, R. Østerby, and E. Ritz Diabetic nephropathy B.M. Brenner S. Levine The Kidney sixth ed. 2000 W.B. Saunders Philadelphia 1731 1773
2. American Diabetes Association Diabetic nephropathy Diabetes Care 25 Suppl. 1 2002 S85 S89
3. A. Grenfell, and P.J. Watkins Clinical diabetic nephropathy: natural history and complications Clin. Endocrinol. Metab. 15 1986 783 805
4. R. Donnelly, J.M. Yeung, and G. Manning Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes J. Hypertens. 21 1 2003 S7 S12
5. S.F. Dinneen, and H.C. Gerstein The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus A systemic overview of the literature Arch. Intern. Med. 157 1997 1413 1418
6. C.E. Mogensen Microalbuminuria and hypertension, with focus on type 1 and type 2 diabetes J. Intern. Med. 254 2003 45 66
7. R.A. Hamilton, M.P. Kane, and J. Demers Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis Pharmacotherapy 23 2003 909 915
8. A.V. Kshirsagar, M.S. Joy, S.L. Hogan, R.J. Falk, and R.E. Colindres Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Am. J. Kidney Dis. 35 2000 695 707
9. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy N. Engl. J. Med. 329 1993 1456 1462
10. H.E. Lebovitz, T.B. Wiegmann, and A. Cnaan Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria Kidney Int. 45 Suppl. 1994 S150 S155
11. J.M. Flack, R. Peters, T. Shafi, H. Alrefai, S.A. Nasser, and E. Crook Prevention of hypertension and its complications: theoretical basis and guidelines for treatment J. Am. Soc. Nephrol. 14 Suppl. 2 2003 S92 S98
12. D. Kirpichnikov, and J.R. Sowers Role of ACE inhibitors in treating hypertensive diabetic patients Curr. Diab. Rep. 2 2002 251 257
13. R. Pisoni, R. Faraone, P. Ruggenent, and G. Remuzzi Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency J. Nephrol. 15 2002 428 430
14. C.A. Visscher, D. de Zeeuw, and P.E. de Jong Angiotensin-converting enzyme inhibition-induced changes in hippurate renography and renal function in renovascular hypertension J. Nucl. Med. 37 1996 482 488
15. F. Ruschitzka, G. Noll, and T.F. Luscher Angiotensin converting enzyme inhibitors and vascular protection in hypertension J. Cardiovasc. Pharmacol. 34 Suppl. 1 1999 S3 S12
16. M. Ruzicka, and F.H. Leenen Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension Drugs 61 2001 943 954
17. U.C. Brewster, and M.A. Perazella Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy? Expert Opin. Drug Saf. 3 2004 9 23
18. A.H. van den Meiracker, A.J. Man in't Veld, and P.J. Admiraal Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. 10 1992 803 812
19. A.H. Chester, and J.A. Borland Chymase-dependent angiotensin II formation in human blood vessels J. Hum. Hypertens. 14 2000 373 376
20. G. Deferrari, M. Ravera, and V. Berruti Treatment of diabetic nephropathy in its early stages Diabetes Metab. Res. Rev. 19 2003 101 114
21. A.H. Barnett, S.C. Bain, and P. Bouter Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy N. Engl. J. Med. 351 2004 952 961
22. M.S. Weinberg, N. Kaperonis, and G.L. Bakris How high should an ACE inhibitor or an angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr. Hypertens. Rep. 5 2003 418 425
23. G. Boner, Z. Cao, and M.E. Cooper Combination antihypertensive therapy in the treatment of diabetic nephropathy Diabetes Technol. Ther. 4 2002 313 321
24. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension Adv. Ther. 15 1998 206 217
25. W.B. White, Y. Lacourcière, and G. Davidai Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period Am. J. Hypertens. 17 2004 347 353
26. Y. Lacourcière, J-M. Krzesinski, W.B. White, G. Davidai, and H. Schumacher Sustained antihypertensive activity of telmisartan compared with valsartan Blood Press. Monit. 9 2004 203 210
27. World Health Organization Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation 1999 World Health Organization Geneva
28. 2 Clin. Chem. 29 1982 2026 2030
29. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem. 18 1972 499 502
30. L.M. Ruilope, J.C. Aldigier, C. Ponticelli, P. Odden-Stock, F. Botteri, and J.F. Mann Safety of the combination of valsartan and benazepril in patients with chronic renal disease J. Hypertens. 18 2000 89 95
31. I.E. Mogensen, S. Neldam, and I. Tikkanen Randomized controlled trial of dual blockade of renin-angiotensin system with hypertension, microalbuminuria and non-insulin-dependent diabetes: the candesartan lisinopril microalbuminuria (CALM) study Br. Med. J. 321 2000 1440 1444
32. P. Jacobsen, S. Andersen, K. Rossing, B.R. Jensen, and H.H. Parving Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy Kidney Int. 63 2003 1874 1880
33. K. Rossing, P. Jacobsen, L. Pietraszek, and H.H. Parving Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial Diabetes Care 26 2003 2268 2274
34. J.T. Shumway, and S.R. Gambert Diabetic nephropathy - pathophysiology and management Int. Urol. Nephrol. 34 2002 257 264
35. A. Mohanram, and R.D. Toto Outcome studies in diabetic nephropathy Semin. Nephrol. 23 2003 255 271
36. T.J. Allen, Z. Cao, S. Youssef, U.L. Hulthen, and M.E. Cooper Role of angiotensin II and bradykinin in experimental diabetic nephropathy Functional and structural studies Diabetes 46 1997 1612 1618
37. R.W. Fuller, C.M. Dixon, and F.M. Cuss Bradykinin-induced bronchoconstriction. Mode of action Am. Rev. Respir. Dis. 135 1987 176 180
38. T.L. Goodfriend, M.E. Elliott, and K.J. Catt Angiotensin receptors and their antagonists N. Engl. J. Med. 334 1996 1649 1654
39. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N. Engl. J. Med. 345 2001 910 912
40. H.H. Parving Renoprotection in diabetes: genetic and non-genetic risk factors and treatment Diabetologia 41 1998 745 759
41. G. Wamberg, R.R. Plovsing, N.C. Sandgaard, and P. Bie Effects of different angiotensins during acute, double-blockade of the renin system in conscious dogs Am. J. Physiol. Regul. Integr. Comp. Physiol. 285 2003 R971 R980
42. N. Komine, S. Khang, L.H. Wead, and F.B. Gabbai Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels Am. J. Kidney Dis. 39 2002 159 164
43. J. Biollaz, H.R. Brunner, I. Gavras, B. Waeber, and H. Gavras Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade J. Cardiovasc. Pharmacol. 4 1982 966 972